Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554

Confo Therapeutics Initiates Phase 2a Trial for Peripheral Pain Candidate CFTX-1554

Confo Therapeutics announced the initiation of a Phase 2a clinical trial for CFTX-1554, its novel angiotensin II type 2 receptor (AT2R) antagonist for peripheral pain. The first patients have been dosed in this study, which evaluates the efficacy, safety, and tolerability of the candidate. CFTX-1554 is being developed in collaboration with Eli Lilly and Company under a global licensing agreement signed on March 2, 2023. Confo received a USD 40 million upfront payment and is eligible for up to USD 590 million in potential milestone payments per program, plus tiered royalties. This milestone marks the first candidate discovered using Confo's proprietary technology to advance into Phase 2.

• The initiation of the Phase 2a trial for CFTX-1554 represents a significant milestone for Confo Therapeutics, marking the first candidate discovered using its proprietary technology platform to reach this advanced clinical stage. This progression underscores the potential of Confo's approach to identifying novel medicines targeting G-protein coupled receptors (GPCRs) and validates its innovative drug discovery capabilities.
• CFTX-1554 is being developed through a global licensing agreement with Eli Lilly and Company, established on March 2, 2023. Under this agreement, Confo Therapeutics received an upfront payment of USD 40 million and stands to receive up to USD 590 million in potential milestone payments per program, alongside tiered royalties. The deal also includes a co-investment option for Confo in future development programs.
• CFTX-1554 is a novel, non-opioid antagonist of the angiotensin II type 2 receptor (AT2R), a clinically validated target for chronic pain. This candidate aims to provide effective pain relief for peripheral pain without the centrally mediated side effects, such as addiction and sedation, commonly associated with current standard-of-care therapies. Its development addresses an urgent need for well-tolerated and efficacious pain management options.

Addressing the Unmet Needs in Peripheral Pain Management

Current peripheral pain management faces significant therapeutic barriers that limit patient outcomes and quality of life. Despite decades of research and clinical development, patients with peripheral neuropathic pain frequently experience inadequate relief with existing treatments, while systemic adverse effects often prevent optimization of therapeutic dosing. The complexity of pain mechanisms and individual patient variability further compounds these treatment challenges.

• Limited efficacy of systemic treatments - Many patients achieve only partial pain relief with currently recommended first-line oral treatments, with systemic drug approaches often demonstrating insufficient efficacy for neuropathic pain conditions

• Dose-limiting adverse effects - Systemic adverse events frequently prevent clinicians from reaching therapeutically necessary doses, while side effects significantly impact medication adherence and patient tolerance

• Persistent moderate-to-severe pain - Despite compliance with prescribed pain medications, patients continue to experience pain of moderate severity that substantially impacts their quality of life and functional capacity

• Individual treatment complexity - Neuropathic pain management requires highly individualized approaches that must account for side effects, specific pain phenotypes, patient comorbidities, and potential drug interactions

• Limited therapeutic innovation - The FDA has approved only one new drug for painful diabetic neuropathy in the past decade (topical capsaicin patch), highlighting the significant unmet need for novel therapeutic options

• Inadequate comparator performance - When evaluated head-to-head against oral standards of care like pregabalin, alternative treatments such as lidocaine 5% medicated plaster have failed to meet predefined noninferiority criteria

• Need for novel therapeutic targets - The persistent challenges in chronic pain management underscore the critical need to identify and validate new molecular targets beyond current pharmacological approaches

AT2R Antagonism Advances: A New Frontier in Pain Management?

The initiation of a Phase 2a trial for CFTX-1554 represents a pivotal moment for Confo Therapeutics and its partner Eli Lilly, signaling a serious commitment to exploring a novel mechanism for peripheral pain. This AT2R antagonist builds upon prior clinical signals from EMA401, which demonstrated consistent, albeit numerically modest, improvements in pain intensity for patients suffering from postherpetic neuralgia and painful diabetic neuropathy. Such findings suggest that modulating the AT2R pathway could offer a much-needed alternative for conditions where existing treatments often fall short.

However, the journey for AT2R antagonists is not without its complexities. The AT2R system is deeply integrated into various physiological processes, and research indicates that AT2R activation can be beneficial in several contexts, including neuroprotection against cerebral ischemia, cardioprotection post-myocardial infarction, and reducing pulmonary fibrosis. This dual nature of AT2R — where antagonism is pursued for pain while activation appears protective in other systems — necessitates careful evaluation of potential off-target effects or safety concerns. A significant risk factor for the class is the preclinical hepatotoxicity observed with EMA401, which led to the premature termination of its Phase 2 trials. While not observed in the short-term human studies, this raises a critical safety consideration for CFTX-1554, particularly with long-term dosing.

Strategically, this Phase 2 entry validates Confo's proprietary technology platform, marking its first candidate to reach this stage. For Eli Lilly, it represents a calculated move into a high-need therapeutic area with a potentially differentiated asset. The success of CFTX-1554 could establish a new class of pain therapeutics, but its development will require meticulous monitoring of both efficacy and safety, especially given the intricate biology of the AT2R and prior class-specific challenges.